

Hajevska M.Yu.

PROBIOTICS AND HEPATOPROTECTORS USAGE IN THE COMPREHENSIVE TREATMENT OF PSORIASIS

*Department of Dermatovenereology,
Bukovinian State Medical University*

Psoriasis is a chronic, systemic immune-mediated disease characterized by the development of erythematous, indurated, scaly, pruritic and often painful skin plaques. Nowadays Psoriasis characterizes whith higher behavior that proves an importance of treatment of psoriatic patients.

The aim is to research the effect of probiotics and hepatoprotectors in a complex psoriasis treatment. 169 patients with psoriasis 89 of them were men and 80 women aged 20-58 years with duration of dermatosis from 10 till 19 years, were observed. To include patients to investigation they should have clinical manifestations of psoriasis, patients age should be 19 years and over dermatosis duration of more than 10 years. To evaluate the clinic manifestations of Psoriasis and to analyze the effectiveness of dermatoses treatment we identify skin affect index and Psoriasis Area Severity Index (PASI) analysis with a help of standard technique. In all patient's pathological process on the skin had a prevailing character, aggravate stage of psoriasis was diagnosed in the majority (118) of patients, 51 patients had stationary stage of the disease. In order to optimize the treatment of patients with Psoriasis we use probiotic Enterozhermina and hepatoprotector in the complex therapy. Hepatoprotector Chophytol can be used both in the acute stage of the disease case (as a detoxicant and donator of nitric oxide) and during the convalescence (as a hepatoprotector). An antagonism towards apportunistic and pathogenic organisms, and activation of lactobacilli breeding and compensation of B vitamins deficiency due to their synthesis, provide probiotic and immunomodulatory Enterozhermina function. In the process of treatment, the patients with psoriasis were divided into 2 groups: 63 patients (comparative group) received fundamental therapy of dermatosis, 106 patients (basic group), taking into consideration the available disease case of hepatobiliary zone, were administered hepatoprotective and probiotic means: - Enterozhermina probiotics (During progressive phase - 3 capsules per day or 1 bottle of suspension 2 times day for 12 days) and Chophytol (0.5g thrice a day during 15 days) stage-by-stage in a complex treatment of dermatosis. The drug usage requires maximum drinking water to normalize the water-electrolyte balance. We have established that the complex therapy of such patients provokes positive dynamics of psoriasis clinical manifestation on the 8-12 day of treatment. The patients showed an improvement in a general condition, their sleep became better, the intensity hyperemia of papules reduced, desquamation decreased. During the final stages of treatment, patients with psoriasis of both groups showed a decrease of index of PASI. However, more significant decrease ,72% of it, was determined in patients of the basic group; in patients of the comparative group-63,2 %. Simultaneously 84 from 106 patients of the basic group showed prolongation (on average to 7-8 months) of the state duration of the clinical remission of dermatosis (in the group of comparison) in 28 out of 63 patients) that allows us to recommend Hepatoprotector Chophytol and Enterozhermina Probiotics use in complex therapy of Psoriasis.

As a result, using hepatoprotector Chophytol as a part of multimodal treatment of psoriasis brings forth the improvement of the results of the patients' therapy and prolongs the duration of clinical remission of the disease. Additionally, Enterozhermina drug proves to be an effective and important component of a complex therapy of adult psoriasis patients of different ages with stable clinical manifestations.

Hulei L.O.

THE INTESTINAL BIOCENOSIS DISORDERS AS KEY FACTOR IN ALLERGODERMATOSES

*Department of Dermatovenereology
Bukovinian State Medical University*

Contact dermatitis (CD) is a common inflammatory cutaneous disease caused by an exposure of contact allergens and irritants on the skin. 4-7% of all dermatology consultations deal with